All Photos(1)

Documents

R1000600

Risperidone

Name: Risperidone
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

R 64,766

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₃H₂₇FN₄O₂

CAS Number:

106266-06-2

Molecular Weight:

410.48

MDL number:

MFCD00274576

UNSPSC Code:

41116107

PubChem Substance ID:

329823994

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

risperidone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

InChI key

RAPZEAPATHNIPO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Risperidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1604676

Y0001276

Risperidone impurity K, European Pharmacopoeia (EP) Reference Standard

1604756

BP1137

Risperidone, British Pharmacopoeia (BP) Reference Standard

BP1158

Risperidone impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictograms

GHS06

Signal Word

Danger

Hazard Statements

H301

Precautionary Statements

P264 - P270 - P301 + P310 + P330 - P405 - P501

Hazard Classifications

Acute Tox. 3 Oral

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity.

Jérôme A J Becker et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(9), 2049-2060 (2014-03-13)

The etiology of Autism Spectrum Disorders (ASDs) remains largely unknown. Identifying vulnerability genes for autism represents a major challenge in the field and allows the development of animal models for translational research. Mice lacking the mu opioid receptor gene (Oprm1(-/-))

PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia.

Christian Spang Pedersen et al.

Behavioural brain research, 273, 63-72 (2014-07-30)

Schizophrenia is a severe psychiatric disorder characterized by three symptom domains, positive (hallucinations, obsession), negative (social withdrawal, apathy, self-neglect) and cognitive (impairment in attention, memory and executive function). Whereas current medication ameliorates positive symptomatology, negative symptoms as well as cognitive

Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients.

Vina M Goghari et al.

Schizophrenia research, 149(1-3), 149-155 (2013-07-09)

Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study

Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?

Katherine Seto et al.

Therapeutic drug monitoring, 33(3), 275-283 (2011-03-26)

Although risperidone is commonly used in the acute and maintenance treatment of schizophrenia, the role of therapeutic drug monitoring has yet to be elucidated. The purpose of this review was to determine whether risperidone warrants therapeutic drug monitoring in patients

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

Csernansky JG

The New England Journal of Medicine, 346(1), 16-22 (2002)

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service